StockNYSE · US · USDHealthcare · Medical Care Facilities
$UHS
UNIVERSAL HEALTH SERVICES INC
Universal Health Services owns and operates acute care hospitals, outpatient facilities and behavioral health care facilities through its subsidiaries. As of February 25, 2026, it owned and/or operated 375 inpatient facilities and 168 outpatient and other facilities in 40 states, Washington, D.C., the United Kingdom and Puerto Rico. Its acute care services include general and specialty surgery, emergency care, internal medicine, obstetrics, radiology, oncology and diagnostic services. Its behavioral health facilities provide inpatient and outpatient care. Universal Health Services also operates a commercial health insurer. It receives payments for healthcare services from private insurers, including managed care plans, Medicare and Medicaid, as well as directly from patients. The company provides its facilities with capital and management services, including purchasing, information services, finance, facilities planning and physician recruitment. Its principal executive offices are in King of Prussia, Pennsylvania.
Universal Health Services (UHS) anticipates a recovery in its hospital operations, with potential growth beyond 2027, despite a $175M-$200M drop in Medicaid payments. The company expects $15M in exchange-related headwinds and increased uncompensated care costs. Q3 saw a 4.9% rise in adjusted admissions and 4.6% increase in ER visits. UHS plans to maintain share repurchases and reduce capital spending in 2027.
RBC Capital kept its Sector Perform rating on Universal Health Services but raised its price target to $207 from $183, suggesting a 5.9% upside from the Nov 10 close of $195.41. Recent analyst price targets for the company range from $156 to $201.
HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.
via TradingView
UHS sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 1 news story mentioning UHS (UNIVERSAL HEALTH SERVICES INC). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent UHS coverage spans financial news, market movers and earnings.
What's driving UHS
Potential downside pressure on UHS as non-recurring Medicaid payments disappear and exchange-related headwinds rise.
AlphAI scores every news story that mentions UHS with an AI model for sentiment and relevance, and aggregates insider trades from UNIVERSAL HEALTH SERVICES INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Universal Health Services (UHS) anticipates a recovery in its hospital operations, with potential growth beyond 2027, despite a $175M-$200M drop in Medicaid payments. The company expects $15M in exchange-related headwinds and increased uncompensated care costs. Q3 saw a 4.9% rise in adjusted admissions and 4.6% increase in ER visits. UHS plans to maintain share repurchases and reduce capital spending in 2027.
RBC Capital kept its Sector Perform rating on Universal Health Services but raised its price target to $207 from $183, suggesting a 5.9% upside from the Nov 10 close of $195.41. Recent analyst price targets for the company range from $156 to $201.
HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.
US hospital operators like HCA, Tenet, and UHS face revenue pressure from rising uninsured patients and reduced government aid. ACA subsidy expiration in 2026 led to premium spikes, causing 3M to drop coverage. HCA estimates a $1.2B income reduction in 2026, with Medicaid cuts expected to further impact profits in 2027 and 2028.
Shares of Medicaid-focused health insurers (Centene, Elevance, Molina) and hospital operators (HCA, Tenet, Universal) rose after Democrats won the midterms, raising hopes for sector-friendly policies. Analysts expect delays in Trump's OBBBA, easing pressure on Medicaid and ACA insurers, and potential extensions of enhanced subsidies. Year-to-date gains vary among companies.
Wells Fargo kept its Equal-Weight rating on Universal Health Services but increased its price target to $170 from $166, suggesting a 3.4% downside from the last close at $176.05.
HCA, Tenet, Community Health, and Universal Health reported declines in elective surgeries due to insurance loss and rising costs. HCA saw inpatient surgeries fall 1.4% and outpatient surgeries drop 3.7%, while ER visits rose 5.1%. Tenet's surgeries slipped 0.7%, and Community Health saw demand below expectations. Executives cited coverage loss and affordability as key factors.
Baird kept its Neutral rating on Universal Health Services but cut its price target to $156 from $166, a 6% reduction. This implies a 9.4% downside from the Oct 28 close of $172.18.
Guggenheim reduced its price target for Universal Health Services (UHS) to $201 from $209, citing weak Q3 2026 EBITDA and macro pressures. UHS stock is down 8.5% in a week. The company lowered its 2026 EBITDA guidance but sees potential upside from expansions. UHS reported Q3 EPS of $5.22 and revenue of $4.73B, slightly beating estimates. Raymond James kept a Market Perform rating, noting softer profit trends and a cautious 2027 outlook.
Raymond James maintained a Market Perform rating on Universal Health Services (UHS), citing Q3 results slightly below expectations and a cautious 2027 outlook. UHS stock is down 21% YTD, trading at $172.18. Analysts have lowered earnings estimates due to slower growth at new facilities. Despite near-term challenges, UHS is trading at a P/E ratio of 6.89, suggesting potential undervaluation.